We recently published a list of 10 AI News and Ratings Too Important to Miss. In this article, we are going to take a look at ...

Despite focused efforts to improve the diversity of clinical trials, representation in research into head and neck cancer has become less equitable over the past decade, according to retrospective ...

More than 10 million babies have been born through IVF, yet the process is still invasive and costly. Plus, why a venture ...

Suzetrigine (Journavx) is the first new drug approved to treat acute pain in over 20 years and the first to be classified as ...

When Aleta was first diagnosed with lupus, she wasn’t ready to share her diagnosis with anyone beyond her closest family and ...

Yunu, creator of the leading clinical trial imaging software platform, announced a strategic partnership with IgniteData to offer sponsor customers Yunu-managed workflows that create connectivity ...

The drug, Journavx, from Vertex Pharmaceuticals, reduced pain after surgery in clinical trials. Experts hope it can lead to fewer opioid prescriptions.

According to research, PSAT1, PSRC1, COLEC12, HP, and PLLP may play a role in small cell lung cancer metabolism, immune ...

Despite high demand for an option like Journavx, doctors fear the drug’s price could be a major hangup for insurers, ...

The drug, Journavx by Vertex Pharmaceuticals, blocks pain signals to the brain, making it nonaddictive. The Food and Drug ...

LONDON - OKYO Pharma Limited (NASDAQ: OKYO), a biopharmaceutical company engaged in developing treatments for ocular ...

The U.S. Food and Drug Administration (FDA) on Thursday approved a new type of prescription pain medication for adults to ...